Premium
Cutaneous S100‐negative, CD 1a‐positive histiocytosis successfully treated with combination therapy of oral methotrexate and corticosteroid
Author(s) -
Takahashi Chiaki,
Kaneta Kazuhiro,
Nomura Wakana,
Ohishi Yasushi,
Uehara Jiro,
Honma Masaru,
IshidaYamamoto Akemi,
Sato Hidetsugu,
Takagi Akiyoshi,
Iizuka Hajime
Publication year - 2015
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.12944
Subject(s) - birbeck granules , s100 protein , histiocyte , medicine , methotrexate , pathology , histiocytosis , dermatology , immunology , immunohistochemistry , antigen , langerhans cell , disease
S 100‐negative, CD 1a‐positive histiocytosis is a rare histiocytic disorder characterized by proliferation of histiocytic cells possessing a phenotype of epidermal Langerhans cells except for the lack of S 100 expression and Birbeck granules. We report the case of a Japanese man suffering from S 100‐negative, CD 1a‐positive histiocytosis. The patient showed numerous smooth erythematous 5–10‐mm papules/nodules on most of his body. The key histopathological feature was the presence of dermal infiltrates of non‐epidermotropic S 100‐negative CD 1a‐positive mononuclear cells. No systemic involvement was detected. Initially bath‐psoralen plus ultraviolet A therapy was effective, but the lesions became recalcitrant to this treatment. Methylprednisolone pulse therapy followed by low‐dose methotrexate (up to 30 mg/week) in combination with prednisolone (15 mg/day) effectively controlled the skin lesions.